{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:50:06Z","timestamp":1781419806029,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Strategic Priority Research Program of CAS","award":["XDB29040102"],"award-info":[{"award-number":["XDB29040102"]}]},{"name":"Strategic Priority Research Program of CAS","award":["XDA12010308"],"award-info":[{"award-number":["XDA12010308"]}]},{"name":"National Key Basic Research Program of China","award":["2015CB553705"],"award-info":[{"award-number":["2015CB553705"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81522030"],"award-info":[{"award-number":["81522030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672464"],"award-info":[{"award-number":["81672464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31600723"],"award-info":[{"award-number":["31600723"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730097"],"award-info":[{"award-number":["81730097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472282"],"award-info":[{"award-number":["81472282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Sci-Tech Special Project of China","award":["2018ZX10302204003"],"award-info":[{"award-number":["2018ZX10302204003"]}]},{"name":"Shanghai Education Committee of Shuguang Plan","award":["18SG32"],"award-info":[{"award-number":["18SG32"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.phrs.2020.104800","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T01:56:23Z","timestamp":1586310983000},"page":"104800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma"],"prefix":"10.1016","volume":"157","author":[{"given":"Yanan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-8078","authenticated-orcid":false,"given":"Geoffrey J.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9822","key":"10.1016\/j.phrs.2020.104800_bib0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.104800_bib0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104800_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3449","article-title":"Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma","volume":"13","author":"Arzumanyan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2020.104800_bib0020","first-page":"396","article-title":"The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma","volume":"1","author":"Yang","year":"2014","journal-title":"Sci. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2020.104800_bib0025","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","article-title":"Diagnosis and treatment of hepatocellular carcinoma","volume":"134","author":"El-Serag","year":"2008","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.phrs.2020.104800_bib0030","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2020.104800_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104800_bib0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.104800_bib0050","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbcan.2017.10.002","article-title":"New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies","volume":"1868","author":"Niu","year":"2017","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2020.104800_bib0055","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/hep.26224","article-title":"Hypoxia\u2010mediated sorafenib resistance can be overcome by EF24 through Von Hippel\u2010Lindau tumor suppressor\u2010dependent HIF\u20101\u03b1 inhibition in hepatocellular carcinoma","volume":"57","author":"Liang","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2020.104800_bib0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/gutjnl-2015-309501","article-title":"Tumour initiating cells and IGF\/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma","volume":"66","author":"Tovar","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.110.175786","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"337","author":"Chen","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2020.104800_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174153","article-title":"Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines","volume":"12","author":"Haga","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2020.104800_bib0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2016.69.5197","article-title":"Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials","volume":"35","author":"Jackson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104800_bib0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ccr.2012.07.023","article-title":"TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma","volume":"22","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.phrs.2020.104800_bib0090","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-11-1156","article-title":"Targeting regulatory T cells in cancer","volume":"71","author":"Byrne","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104800_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma","volume":"62","author":"Yeung","year":"2015","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2020.104800_bib0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","article-title":"CCR4 as a novel molecular target for immunotherapy of cancer","volume":"97","author":"Ishida","year":"2006","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.phrs.2020.104800_bib0110","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.bjc.6605689","article-title":"Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma","volume":"102","author":"Wang","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"7593","key":"10.1016\/j.phrs.2020.104800_bib0115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"issue":"4 Pt 1","key":"10.1016\/j.phrs.2020.104800_bib0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1053\/jhep.2002.35532","article-title":"Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B","volume":"36","author":"Leifeld","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(97)70235-X","article-title":"Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections","volume":"112","author":"Bertoletti","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","article-title":"A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma","volume":"25","author":"Goyal","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2020.104800_bib0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.104800_bib0140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccr.2007.08.029","article-title":"Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis","volume":"12","author":"Petersen","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2020.104800_bib0145","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","article-title":"TNF-alpha induces two distinct caspase-8 activation pathways","volume":"133","author":"Wang","year":"2008","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bmc.2008.11.020","article-title":"Potent and orally bioavailable CCR4 antagonists: Synthesis and structure\u2013activity relationship study of 2-aminoquinazolines","volume":"17","author":"Yokoyama","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0030-1247128","article-title":"Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis","volume":"30","author":"Sherman","year":"2010","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.phrs.2020.104800_bib0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.phrs.2020.104800_bib0165","article-title":"Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104800_bib0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ebiom.2017.07.014","article-title":"A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer","volume":"22","author":"Yao","year":"2017","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.phrs.2020.104800_bib0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tranon.2018.01.001","article-title":"Dendritic cells pulsed with exosomes in combination with PD-1 antibody increase the efficacy of sorafenib in hepatocellular carcinoma model","volume":"11","author":"Shi","year":"2018","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2020.104800_bib0180","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.phrs.2020.104800_bib0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.phrs.2020.104800_bib0190","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1177\/0091270010386226","article-title":"Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial","volume":"51","author":"Awada","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.phrs.2020.104800_bib0195","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.phrs.2020.104800_bib0200","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/ijc.27925","article-title":"Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial","volume":"132","author":"Chung","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"13","key":"10.1016\/j.phrs.2020.104800_bib0205","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:07:37Z","timestamp":1760911657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820311087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"alternative-id":["S1043661820311087"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104800","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104800"}}